The sector has continued to outperform others with the Stockholm’s healthcare index (SX20PI) being up 126% (AstraZeneca up 76%) over the last five years compared with 68% for the OMXS30. But also well-beyond the few included in Stockholm’s healthcare index we have seen tremendous progress of companies across all subsectors (biotech, diagnostics, medtech, digitalhealth). Noticeable was a wave of medtech companies reaching the market, where they have cleared or are just about to clear their initial sales struggles.
Biotech is however also catching up, with progress reported in various disease areas, where formerly research-stage companies are growing into larger clinical-stage companies with some reaching market approval and reporting their first quarters of sales. We believe that the sector remains highly attractive, resilient in crisis as shown in the past and now during the pandemic and despite the individual company risk, the Nordic healthcare sector moves forward at ever-faster pace.
See the full agenda and register for the virtual seminar.
Please note, you must be a registered client to attend.